RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 11 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. ECOG performance status score ≤ 2;

    Inclusion criterion 3

  3. Pregnant or breastfeeding women;

    Exclusion criterion 16

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07496229, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed informed consent;
  • Adult ≥ 18 years of age;
  • ECOG performance status score ≤ 2;
  • Life expectancy of not less than 12 weeks;
  • Histopathologically confirmed diagnosis of PTCL;
  • Presence of measurable disease;
  • Adequate bone marrow function and vital organ function reserve;
  • Ability to comply with study requirements and to complete study-related procedures;
  • Adequate contraception during participation in the trial.

Exclusion Criteria:

  • Presence of unresolved drug-related adverse events greater than Grade 1;
  • Lymphoma involving the central nervous system;
  • Failure to complete the required washout period for other anti-tumor therapies;
  • Corticosteroid use that does not meet protocol requirements;
  • Major surgery/trauma within a short period, or planned major surgery within a short period;
  • Vaccination with a live vaccine within a short period;
  • Inability to discontinue prohibited medications;
  • Requirement for immunosuppressive agents or biologics due to an underlying disease;
  • Presence of active infection;
  • Significant cardiovascular disease;
  • Presence of gastrointestinal disease that might affect drug intake or absorption;
  • History of other malignancies;
  • Known allergy to the study drug;
  • Other severe or uncontrolled systemic diseases;
  • Personnel with a conflict of interest (e.g., site staff, sponsor employees);
  • Pregnant or breastfeeding women;
  • Inability to comply with protocol requirements.

Quoted from ClinicalTrials.gov, NCT07496229, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07496229, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07496229